Plain-English translation of NCT05422534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether CoQ10, a natural compound that helps cells produce energy, combined with exercise can help people with end-stage kidney disease rebuild muscle strength and reduce frailty. Many dialysis patients experience unusual weakness and muscle loss at younger ages than the general population, and researchers believe that improving how cells work—particularly the energy-producing structures called mitochondria—may help reverse this. The study will compare CoQ10 alone, exercise alone, both together, or neither over 12 weeks.
About 73% of people starting dialysis experience frailty and muscle weakness, which makes everyday activities harder and increases health risks. Current standard care doesn't always address the root cause: cells may not be producing energy efficiently, making muscles weak even when muscle size seems adequate. This trial explores whether boosting cellular energy production and building strength through exercise can prevent or reverse this debilitating condition.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to one of four groups for 12 weeks: taking a placebo pill with standard care, taking CoQ10 1800 mg daily with standard care, doing supervised home exercise three times per week (on non-dialysis days via video), or combining CoQ10 with the exercise program. The exercise sessions include three different types per week—bodyweight high-intensity training, strength training, and walking intervals—each video-supervised to ensure safety. Throughout the study, researchers will monitor your muscle strength, physical function, and overall frailty using standard fitness tests.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States